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Processing of the retroviral gag and pol gene products is mediated by a viral protease. Bacterial expression
systems have been developed which permit genetic analysis of the human immunodeficiency virus type 1
protease as measured by cleavage of the pol protein precursor. Deletion analysis of the pol reading frame locates
the sequences required to encode a protein with appropriate proteolytic activity near the left end of the pol
reading frame but largely outside the gag-pol overlap region, which is at the extreme left end of pol. Most
missense mutations within an 11-amino-acid domain highly conserved among retroviral proteases and with
sequence similarity to the active site of aspartic proteinases abolish appropriate processing, suggesting that the
retrovirus proteases share a catalytic mechanism with aspartic proteinases. Substitution of the amino acids
flanking the scissile bond at three of the processing sites encoded by pol demonstrates distinct sequence
requirements for cleavage at these different sites. The inclusion of a charged amino acid at the processing site
blocks cleavage. A subset of these substitutions also inhibits processing at the nonmutated sites.
The pol gene of retroviruses generally encodes three
distinct proteins: a protease (PR) encoded at the 5' end of the
gene; the reverse transcriptase-RNase H (RT) in the center
of the gene; and the integration protein (IN) encoded at the
3' end of the gene. Expression ofpol is controlled at the level
of translation. The pol gene is expressed as a fusion protein
with gag (encoded upstream of po) after either termination
suppression (when gag and pol are in the same reading frame
[46]) or a frameshifting event (when gag and pol are in
different partially overlapping reading frames [18-20, 32,
47]). The gag and pol gene products are processed out of the
gag and gag-pol precursors by the pol-encoded PR (7, 43,
44, 48). Processing is an obligatory step in the virus life
cycle, since mutations in the PR domain result in the
production of noninfectious virus with unprocessed gag and
gag-pol precursor proteins (3, 22, 23).
Genetic evidence suggests that in the human retrovirus
human immunodeficiency virus type 1 (HIV-1), the etiologic
agent of acquired immunodeficiency syndrome, an analo-
gous PR activity is encoded at the 5' end of the pol reading
frame (8, 23, 26, 33), and a small domain from this region of
the genome has been expressed in Escherichia coli to give a
PR capable of cleaving the gag or pol precursor (5, 9). This
region encodes amino acids that are conserved among ret-
roviruses, and some of these amino acids share sequence
identity with the active site of aspartic proteinases (40). The
sequence of the amino terminus of an 11-kilodalton (kDa)
virion protein (pll), thought to be the PR, has been deter-
mined previously (30). The other proteins encoded within
the HIV-1 pol gene are two forms of the RT that share a
common amino terminus but differ in molecular mass (64 and
51 kDa; p64 and p5i, respectively [6, 29]), a protein of 15
kDa that has RNase H activity (12), and a protein of
molecular mass 34 kDa (p34) which is the presumed viral
integration protein (29). For these proteins to be generated,
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at least four processing events must occur within the pol
portion of the gag-pol precursor (Fig. 1A).
We and others have developed bacterial expression sys-
tems in which the HIV-1 pol gene is expressed and its
primary translation product is processed to give proteins
similar in size to those found in virus particles (8, 13, 28, 30).
Analogous expression systems have been described for the
PR of the avian retrovirus Rous sarcoma virus, in which the
PR is encoded by gag (25, 31). The appearance of these viral
proteins is dependent on coexpression of the presumed viral
PR domain, indicating that processing in this system is
mediated by the pol-encoded protease. The use of heterolo-
gous expression systems provides a simple and quick assay
for HIV-1 PR function and for processing of the pol precur-
sor. Using this bacterial expression system, we carried out a
series of mutational analyses to study processing of the
HIV-1 pol gene product.
MATERIALS AND METHODS
Plasmid constructions. The 3.7-kilobase-pair BgiII-SalI
fragment from the cloned HIV-1 provirus HXB2 (36) was
subcloned into the BamHI-SalI sites in the polylinker region
of pIBI20 to make pART1. This fragment of the viral genome
contains the entire pol gene with the exception of the first
four codons. In the pIBI20 plasmid, the insert is under the
inducible control of the lac promoter-operator. The fused
BamHI-BglII site at the 5' end of the pol gene insert in
pART1 was converted into a BglII site (to make pART2) by
a single point change (G to A) which did not change the
protein-coding capacity of pART1. The plasmids pBRTlprt'
and pBRT3prt- were previously described (8).
Deletion clone construction. The method of Henikoff (15) as
modified by Hoheisel and Pohl (16) was used to construct
unidirectional deletions in the 5' end of the pol gene. The
plasmid pARTi was linearized by digestion with SstI and
SmaI, two adjacent sites in the polylinker 5' to the pol gene
insert. The SmaI terminus was susceptible to digestion with
exonuclease III and nuclease Si, which resulted in deletions
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FIG. 1. Expression of processed pol gene products in E. coli. (A)
The large box represents the BglII-SalI fragment from the cloned
HIV-1 provirus HXB2 (36), which contains the pol open reading
frame (ORF) with domains (PR, RT, and IN) as indicated. Above
this box are illustrated the four mature products derived from the pol
ORF. The PR is labeled PR pll; the RT is labeled RT p64 and RT
p5l; and the IN is labeled IN p34. The vertical arrows (with the
exception of the one at the right end of the IN domain) represent
protein-processing sites in the pol precursor. Below the large box is
a drawing illustrating features of the pART2 pol expression plasmid:
mm, lac promoter-operator (lac PO); E, protein-coding sequence
contributed by the vector (23 codons of lacZ-polylinker region from
pIBI20). (B) Two Western blots demonstrating the ability of bacteria
containing pART2 to direct the synthesis of the four mature pol gene
products. The left panel is a Western blot of proteins separated by
electrophoresis in a 10% polyacrylamide gel, transferred to nitrocel-
lulose paper, and then stained with a 1:500 dilution of an HIV-1-
seropositive human antiserum. Lanes: V, lysate of pelleted HIV-1;
1, lysate of bacteria expressing pART2; 2, lysate of bacteria express-
ing pBRTlprt+ which is truncated in the IN domain (8); 3, lysate of
bacteria expressing a derivative of pART1 (pART1E2) which has a
frame shift in the polylinker region upstream of the 5' end of the pol
insert (to identify internal initiations); 4, lysate of bacteria contain-
ing pIBI20 (the parent vector). The right panel is a Western blot of
proteins separated in a 15% polyacrylamide gel, transferred to
nitrocellulose paper, and stained with a 1:1,000 dilution of a poly-
clonal rabbit antiserum directed against the C terminus of the HIV-1
PR and the N terminus of the RT (2). Lanes: V, lysate of pelleted
HIV-1; 5, lysate of bacteria expressing pART2; 6, lysate of bacteria
expressing pBRTlprt+; 7, lysate of bacteria expressing pBRT3prt-
which is truncated in both the PR and IN domains (8); 8, same as
lane 3; 9, same as lane 4.
of various lengths extending into the HIV-1 pol insert.
Digestion products were circularized with ligase and recov-
ered as deletion clones by transformation of E. coli JM101.
Design and synthesis of mutagenic oligonucleotides. To
introduce random missense mutations into selected domains
of the PR-coding sequence, two adjacent 39- and 40-base
oligonucleotides were synthesized under conditions such
that an average of 1.5 mutations or misincorporations per
oligonucleotide were achieved as described by Hutchison et
al. (17). To make random changes in the two codons sur-
rounding the scissile bonds of three different cleavage sites
in the pol precursor, we synthesized either a 40-mer (two
cases) or a 38-mer (one case) such that the oligonucleotide
was identical to the wild-type sequence of pART2, except at
the six positions for the two codons, where an equimolar
mixture of all four nucleotide precursors was incorporated
during synthesis.
Mutant library construction. The mutagenic oligonucleo-
tides were used to create libraries of random point mutants
by using a uracil-containing, single-stranded DNA form of
either pART1 or pART2 following the procedure of Kunkel
et al. (27). An equimolar ratio of primer to template was used
during second-strand synthesis on the uracil-containing tem-
plate. The mutant clones were recovered as plasmids by
transformation of E. coli JM101 and selection for ampicillin
resistance. The resulting libraries had a mutant frequency of
greater than 50%.
Genotype screening. Individual clones were used to inoc-
ulate two 1.5-ml cultures to determine their phenotype and
genotype. One inoculated culture of supplemented 2XYT
(1.0% tryptone, 1.0% yeast extract, 0.5% NaCl, 0.001%
thiamine, 100 Kig of ampicillin per ml) was grown at 37°C for
4 h. Then 2 x 109 PFU of M13K07 (42) was added, the
culture was grown for an additional 1 h, and kanamycin was
added to a final concentration of 70 ,ug/ml. The cultures were
grown for an additional 12 to 18 h before harvesting and
preparation of single-stranded DNA for DNA sequence
analysis as described by Bankier et al. (1).
Phenotype screening. An inoculated culture of supple-
mented M9 medium (complete M9 plus 0.2% Casamino
Acids [Difco Laboratories], 0.001% thiamine, 100 ,ug of
ampicillin per ml) was grown 12 to 18 h prior to induction of
the lac promoter-operator with 5 mM isopropyl-,i-D-thioga-
lactopyranoside (IPTG). After a 1- to 2-h induction, bacteria
were lysed in 1/10 volume of loading buffer (62.5 mM Tris
hydrochloride [pH 6.8], 2.3% sodium dodecyl sulfate, 10%
glycerol, 5% ,-mercaptoethanol, 0.05% bromophenol blue)
and heated to 100°C for 3 to 4 min. A 10-,ul portion of each
sample was analyzed on a Western immunoblot as described
by Farmerie et al. (8).
RESULTS
Expression of processed pol gene products in E. coli. We
reported previously that expression of a portion of the HIV-1
pol gene in bacteria resulted in the appearance of the
processed forms of the viral RT (p64 and p51 [8]). These viral
proteins were detected by Western blot analysis with serum
from an HIV-1-seropositive person. Our original pol expres-
sion plasmid was truncated in the IN domain, which pre-
cluded expression of the IN. To determine whether it was
possible to express all of the processed pol gene products
(PR, pll; the two forms of the RT, p64 and pS1; and IN, p34)
in bacteria, we expressed all but the first four codons of the
pol reading frame under the control of an inducible pro-
moter. When an extract prepared from bacteria expressing
this clone (pART1) was examined with the HIV-1-positive
antiserum, a 34-kDa species was present which comigrated
with the presumed viral integrase p34, in addition to the two
forms of the viral RT, p64 and pS1 (Fig. 1B; compare lane V
with lane 1). The p34 species was absent from an extract
prepared from cells expressing the clone truncated in the IN
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domain (Fig. 1B, lane 2). The RNase H protein was not
detected when this antibody reagent was used. When these
extracts were examined with a rabbit polyclonal antibody
raised against a peptide that includes the carboxyl terminus
of the PR and the amino terminus of the RT (2), an 11-kDa
protein was seen which comigrated with a viral protein
approximately 11 kDa in size (Fig. 1B; compare lanes V, 5,
and 6). From this experiment we conclude that the four
mature pol gene products are made in bacterial cells express-
ing the HIV-1 pol reading frame.
In the bacteria that are expressing p64, p51, p34, and pll
there are several additional discrete bands, which react in
the Western blot analysis, the exact sizes of which vary
depending on the antibody used. Several of these bands
represent reactivity with E. coli proteins (Fig. 1B, lane 4 for
reactivity with HIV-1-positive human antiserum and lane 9
for reactivity with rabbit antiserum). The rest of the bands
appear to be the result of internal initiation at methionine
codons. This interpretation is supported by the observation
that the intensity of several bands increases when a termi-
nation codon or frameshift mutation is introduced near the 5'
end of the pol reading frame (Fig. 1B, lane 3 for HIV-1-
positive human antiserum and lane 8 for the rabbit antise-
rum).
In the experiments described below, the appearance of
p64, p51, p34, and pll has been used as an indication of
normal processing. The identity of the two forms of the RT
has been confirmed by reaction with two separate monoclo-
nal antibodies to the HIV-1 RT (data not shown). The
identities of p34 and pll were confirmed during mutational
analysis of the processing sites at their respective amino
termini (see below); p34 was also identified by deletion
analysis (Fig. 1B, lane 2) and by reactivity with a monospe-
cific rabbit antibody directed against a peptide synthesized
to correspond to a portion of the IN domain (data not
shown).
Deletion analysis of the pol reading frame. In the HIV-1
genome, the 3' end of the gag reading frame overlaps the 5'
end of the pol reading frame by 205 or 241 base pairs (205
base pairs for the provirus from which pART1 was derived
[36]). The frame shift from the gag reading frame to the pol
reading frame has been shown to occur at codon 3 of the pol
reading frame (18). The amino terminus of the virion protein
believed to be the mature PR is encoded by codon 57 of the
pol reading frame (30). Ninety-nine codons downstream is
the codon for the amino terminus of the mature RT (p64 and
pS1 [6, 25]). To determine the boundary of the domain
required to encode PR function, we constructed a series of
deletions at the the 5' end of the pol gene. The two smallest
deletions, extending to codons 31 and 40 of the pol reading
frame, had no effect on the appearance of p64, pS1, and pll,
the wild-type products that would be detected with the
antiserum used in this experiment (Fig. 2, lanes 1 and 2).
Deletions beyond this point and up to codon 53 of the pol
reading frame (lanes 3 to 5) showed the processed pol gene
products with the concomitant appearance of several larger
species. Deletions starting at and beyond codon 56 (lanes 6
to 16) failed to express pll, the mature form of the PR,
which was replaced with a series of larger proteins that
presumably are the result of degradation of the pol precursor
by bacterial proteases. With the exception of a deletion
extending to codon 59 (lane 8), these deletion mutants also
failed to express p64 and p51, and, instead, several new
high-molecular-weight species appeared. Thus, deletions to
codon 53 do not affect the ability to encode accurate cata-
lytic activity of the PR, nor do they result in the loss of
amino acids required for recognition of the N-terminal
processing site of the PR.
Missense mutations within a highly conserved domain of the
PR-coding region. Toh et al. (40) reported sequence identity
between the amino acid sequence of retroviral PRs and the
active site of aspartic proteinases. This region of identity is
embedded within a larger domain (amino acids 23 through
33) that is conserved among retroviral PRs (Fig. 3). We used
oligonucleotide-directed mutagenesis to determine the sen-
sitivity of the HIV-1 PR activity to missense mutations
within this relatively conserved domain that includes se-
quence identity with aspartic proteinases. Mutations were
introduced by using a randomly mutagenized oligonucleotide
(39 nucleotides in length spanning codons 21 through 33) to
prime DNA synthesis on a single-stranded DNA template
containing the HIV-1 pol gene. We observed three different
phenotypes of processing among the mutants, similar to the
phenotypes seen in the deletion analysis. First was a pheno-
type that was indistinguishable from the wild type. Second
was a phenotype which showed some appropriately proc-
essed products and also some larger unprocessed and par-
tially processed products. Third was a phenotype which
showed no normal processing. Examples of the mutant
phenotypes are shown in Fig. 4, in which paired conserva-
tive and nonconservative substitutions are presented for
each amino acid position in this domain.
The phenotypes of all of the mutants tested for this
conserved region are shown in Table 1 and can be summa-
rized as follows. Of the 13 codons covered by the mutagenic
oligonucleotide, 11 were altered to give 36 independent
substitutions; in nine of the positions both conservative and
nonconservative substitutions were tested. Of the 36 mis-
sense mutations, 25 (69%) resulted in no normal processing.
Of the 11 mutations which allowed some level of normal
processing, the extent of processing after mutagenesis was
similar to the wild type at only two positions (Glu-21 to Val
and Asp-30 to Glu). The sequence Asp-Thr-Gly-Ala-Asp
(Table 1, positions 25 through 29), which includes the
residues with sequence identity to the active site of aspartic
proteinases, was extremely sensitive to mutation. All muta-
tions except for one resulted in no normal processing (no
missense mutations were recovered at the Gly-27 residue).
Only an Ala-to-Ser mutation at position 28 was tolerated,
and even this mutant had a very low level of normal
processing (Fig. 4, lane 15). At the remaining five positions
tested (Ala-22, Leu-23, Leu-24, Thr-31, and Val-32), only
conservative changes were tolerated to permit even partial
processing (Table 1).
Mutational analysis within the adjacent 13-amino-acid
domain (Fig. 3, positions 34 through 46), which is less
conserved evolutionarily, showed a lower percentage of
aberrant phenotypes (Fig. 5; Table 2). Only 5 of 27 substi-
tutions (19%) resulted in no normal processing. Of the 22
substitutions which permitted processing, 19 resulted in
processing that was very similar to that of the wild type.
Within this region, only three amino acids are identical
between HIV-1 and HIV-2 (Leu-38, Pro-44, and Lys-45),
and even these positions could be substituted without af-
fecting processing. These results show that the region of the
PR that shares sequence identity with the active site of
aspartic proteinases is highly sensitive to mutation, consis-
tent with the hypothesis that HIV-1 PR is an aspartic
proteinase.
Mutagenesis of three processing sites within the HIV-1 pol
precursor protein. At least four processing events take place
within the pol precursor protein: a cleavage upstream of the
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FIG. 2. Deletion analysis of the 5' end of the pol reading frame. The rectangular boxes indicate the arrangement of the gag and pol open
reading frames (ORF), with the position of the N terminus of the virion form of the PR indicated (see text). The numbering inside the pol open
reading frame indicates the codon number from the beginning of the reading frame. Vertical lines between the top of the box representing the
pol open reading frame and the lanes in the Western blot identify the deletion endpoints with their corresponding phenotype. Lanes: B, lysate
of bacteria containing pIBI20, I, lysate of bacteria expressing pART1E2; V, lysate of pelleted HIV-1; WT, lysate of bacteria expressing
pART1; 1 through 16, deletions of the HIV-1 pol open reading frame whose right endpoints are indicated by the lines pointing to the box of
the pol open reading frame below. (A) Western blot of proteins electrophoresed in a 10% polyacrylamide gel, transferred to nitrocellulose
paper, and stained with a 1:100 dilution of a monoclonal antibody that recognizes RT p64 and RT pS1 (6). (B) Western blot of proteins
electrophoresed in a 15% polyacrylamide gel, transferred to nitrocellulose paper, and then stained with a 1: 1,000 dilution of a rabbit polyclonal
antiserum that recognizes PR pll (2).
PR to generate the amino terminus of the mature protease; a
cleavage between the PR and the RT; a cleavage within the
RT to generate its smaller form (p51); and a cleavage







cleavages have been identified by amino-terminal sequence
analysis of the mature viral protein product (PR, RT, and IN
[6, 29, 30]). We have used oligonucleotide-directed mutagen-
esis to create missense substitutions in the amino acids
1 *10 * 20 ******* *** 40 *
PQITLWQRPLVTIRIGGQLK EALLDTGADDTVLEEKSLPGRWXPXM
PQfSLWkRPVVTayIeGQpv EvLLDTGADDSIVagIeLGnnYsPXI
yvVTe apPkIeIKVGTrwK klLVDTGADkTIVtshdMSG iPKgri i
lamtMehkDRPLVrViLTntgshpvkqrsvyitALLDSGADiTIIsEedw PtdwPvMeaanpq
lsipLA rsRPsVAVyLSGpwlqpsqnqa lmLVDTGAENTVL pqnwlvRdyPRIpaa
tlddqGgqGqeppPeprItLkvggqpv tfLVDTGAQhSVLtQnPgPlsdKSaw
60 * 70 * * ***** * *99
HIV 1 IGGIGGFIKVRQYDQILIEIC GEKAIGTVL VGPTPV NIIGRNLLTQIGCTLNF
HIV 2 VGGIGGFIntKEYkNVeIEV1 nKXvrATIM tGdTPI NIfGRNILTaLGmSLN1
Visna LqGIGGiIegekWEQVhLQyk dKmikGTIVvLATSPV EVLGRDnMrELGiGLima
RSV IhGIGGgIpMR ksrdMIELgvi nrdgslerPLLlfPAvAMvrgsILGRDcLqgLGlrLtnl
BLV VlGaGGvsRnR YNw LQgpltlalkPegPfiTIpkIlvdTfdkwQILGRDVLSrLqaSIsip
MuLV VqGaTGgkRyRwttDrkVhLa TgKvthSfLhVPdcPy pLLGRDLLTkLkaqIhFe
FIG. 3. Amino acid sequence alignment of the HIV-1 PR domain with other inferred or known retroviral PR domains. Viruses: HIV-1,
from pART2 (same in reference 36 except for position 3); HIV-2, HIV type 2 (10); Visna, visna virus (38); RSV, Rous sarcoma virus (37);
BLV, bovine leukemia virus (47); MuLV, murine leukemia virus (46). All sequences are compared with the HIV-1 sequence. Amino acid
identity between the HIV-1 sequence and a second sequence is indicated with a bold capital letter in the second sequence. A favored
substitution (4) between HIV-1 and a second sequence is indicated as a capital letter in the second sequence. Lowercase letters indicate a lack
of either an identity or a favored substitution between the second sequence and HIV-1. For positions where all residues are in capitals
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FIG. 4. Missense mutations within a highly conserved domain of the PR-coding region. Lysates of bacteria expressing the pART2 plasmid
with the indicated mutations were analyzed by Western blot analysis with a 10% polyacrylamide gel and an HIV-1-positive human antiserum.
The wild-type HIV 1 sequence is shown at the top in the three-letter amino acid designation. The mutants tested are shown with the
single-letter amino acid designation over the lane which shows the phenotype of that mutant (lanes 1 through 24). Paired conservative and
nonconservative changes are shown for each position in the wild-type sequence (residues 21 through 32 [Fig. 3]). A (-) indicates that no
mutation was tested at that position. The positions of the two forms of the RT, RT p64 and RT p51, and IN p34 are indicated. Lane B, lysate
of bacteria containing pIBI20; lane I, lysate of bacteria expressing pART1E2; lane WT, lysate of bacteria expressing pART2; lane V, lysate
of pelleted HIV-1.
flanking the scissile bond (P1 and P1') to examine sequence
requirements of the substrate for cleavage by the viral PR.
Examples of the phenotypes of these mutants are shown in
Fig. 6, and the phenotypes of all of the mutants tested are
summarized in Table 3.
In total, 50 of the possible 400 dipeptide combinations
were tested at the three processing sites. Of the 20 amino
acids, 17 appeared in P1 (His, Gln, and Tyr were not tested),
whereas 18 were tested in P1' (Val and Glu were not tested).
In the substitutions that permitted some level of processing,
three amino acids appeared only in P1 (Leu, Val, and Phe),
five amino acids appeared only in P1' (Ser, Thr, Pro, His,
and Ile), and two amino acids appeared in both positions
(Gly and Ala).
The cleavage site between RT and IN was the most
sensitive to mutagenesis. All 17 mutants tested had a single
phenotype: a fusion protein between the RT (p64) and IN
(p34) (Fig. 6, lanes 7 to 9). There was no apparent effect on
the processing of pSi. Several minor species were present at
the position of p64. The source of these p64-like species is
not understood, but could be the result of cleavage at nearby
secondary and/or cryptic sites or processing by bacterial
enzymes. This background could have obscured a partial
cleavage phenotype, although in no case was the IN protein
detected.
Nineteen substitutions were tested at the PR-RT cleavage
site (examples are shown in Fig. 6, lanes 4 to 6). In two
mutants, only one of the two amino acids was changed:
Phe-Pro to Phe-Ser permitted partial processing, while Phe-
Pro to Glu-Pro blocked processing. Two double substitu-
tions also permitted partial processing. This occurred when
either Leu or Val was substituted for Phe in the P1 position
and Gly was substituted for Pro in the P1' position.
The 17 substitution mutants that were tested at the up-
stream PR cleavage site gave phenotypes that fell into three
categories (Fig. 6, lanes 1 to 3). Five of the mutations
permitted processing at the upstream cleavage site and at the
other cleavage sites to generate RT and IN (Gly-Ala, Gly-
His, Leu-Thr, Leu-Pro, and Ala-Ile). The second group of
mutants apparently failed to cleave at the mutated upstream
PR cleavage site, but cleavage still occurred at the PR-RT
and RT-IN cleavage sites (Val-Arg, Arg-Thr, Ser-Thr, Gly-
Arg, and Lys-Arg). In these mutants the PR pll species was
absent and was replaced by a series of higher-molecular-
weight species (Fig. 6, lane 2). Thus, the processing seen
with these mutants was the result of either a small amount
(undetected) of mature PR or a larger form of the PR that
retained activity. The third group (Leu-Phe, Val-Pro, Asp-
Ser, Asn-Ser, Trp-Tyr, Ile-Pro, and Ile-Gln) was similar to
the second in that no mature-sized PR was seen; however,
with these mutants only a very low level of processing to
generate RT p64 and IN occurred (Fig. 6, lane 3).
DISCUSSION
We have used a bacterial expression system to examine
the HIV-1 PR encoded within the viral pol gene. In this
system the HIV-1 pol gene is expressed in E. coli under the
control of an inducible promoter. After induction, four
proteins are detected in the bacterial lysate with the same
apparent molecular weights as the four processed pol gene
products found in virions: the PR, pll; two forms of the RT,
p64 and p5l; and the IN, p34 (Fig. 1). This system provides
a simple assay for PR activity, i.e., the generation of
processed viral proteins, and permits rapid manipulation of
the pol gene sequence. We have used this system to probe
the sequence requirements for expression of an active PR
and PR cleavage site.
The HIV-1 PR domain. We were able to delete the first 52
codons of the pol reading frame without destroying PR
activity. This is very close to codon 57, which encodes the
amino acid found at the amino terminus of the virion protein
presumed to be the mature form of the PR (30). Thus, the
deletion analysis is consistent with the protein sequence data
in defining the HIV-1 PR domain as a small region (99 amino
acids based on protein sequence analysis) that lies entirely
within the pol gene and adjacent to the RT domain. This
assignment is further supported by the work of Debouck et
al. (5), which showed that a 382-base-pair fragment from this
region of the pol gene can express a protein in bacteria that
has PR activity and is processed to generate the same amino
terminus as the protein isolated from the virion.
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TABLE 1. Phenotypes of mutants with missense mutations in highly conserved domain of PR-coding region'
Phenotype of mutant with mutation at following codonb:
21 22 23 24 25 26 27 28 29 30 31 32 33
Mutant * * * * * * * * * *
GLU Ala Leu Leu Asp Thr Gly Ala Asp Asp Thr Val Leu




























































































































a Amino acid and codon for wild-type strian are shown below codon numbers for positions 21 to 33. Asterisks denote conserved residues (see Fig. 3).
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FIG. 5. Missense mutations within a poorly conserved domain of the PR-coding region. Analysis similar to that described in the legend
to Fig. 4 was carried out for point mutations in a poorly conserved domain of the protease (residues 34 to 46 [Fig. 3]). All procedures and
notations are as described in the legend to Fig. 4.
Significance of sequence identity with aspartic proteinases.
Retroviral PRs show sequence identity with the active site of
aspartic proteinases (40). This similarity is strengthened by
the observation that pepstatin, an inhibitor specific to aspar-
tic proteinases, inhibits several retroviral PRs, although
inhibition is apparent only at relatively high concentrations
of the inhibitor (11, 21). On the basis of the assumption that
the active site of an enzyme should be one of the most
sensitive sites to mutation with respect to enzyme activity,
we have undertaken extensive mutagenesis of the HIV-1 PR.
TABLE 2. Phenotypes of mutants with missense mutations in less highly conserved domain'
Phenotype of mutant with mutation at following codonb:
Mutant 4 35 36 37 38 39 40 41 42 43 44 45 46
Glu Glu Met Ser Leu Pro Gly Arg Trp Lys Pro Lys Met



































a Amino acid and codon for wild-type strain are shown below codon numbers for positions 34 to 46. For definition of asterisk, see Table 1, footnote a.
b See Table 1, footnote b.
VOL. 63, 1989
118 LOEB ET AL.
FjP F - P L-F
Li












FIG. 6. Mutagenesis of three processing sites within the HIV-1 pol precursor protein. The box at the top represents the pol reading frame
with its four domains: the region upstream of the PR, the PR domain, the RT domain, and the IN domain. The amino acids flanking the scissile
bonds that separate each domain are shown above the box. The positions of the processing sites are inferred from protein sequence data (see
text). Below each box are Western blot analyses of examples ofpol gene mutants with altered processing site sequences. The altered sequence
is shown at the bottom of the lane for lanes 1 through 9. The upper panel of each blot represents analysis of mutants expressed in bacteria
with the bacterial lysate electrophoresed in a 10% polyacrylamide gel and reacted with an HIV-1-positive human antiserum. The lower panel
is an analysis of the same lysates in a 15% polyacrylamide gel and reaction with the rabbit antibody to PR-RT (2). Positions of the wild-type
products, PR (PR pll), RT (RT p64 and RT p51), and IN (IN p34) are indicated. Lane B, lysate of bacteria containing plBI20; lane I, lysate
of bacteria expressing pART1E2; lane WT, lysate of bacteria expressing pART2; lane V, lysate of pelleted HIV-1.
In our initial screen, we mutagenized two adjacent 13-amino-
acid domains (approximately 25% of the PR domain) and
examined the activity of 96 mutants. The first 13-amino-acid
domain, which spans a highly conserved region among
retroviruses and contains the residues that show sequence
identity with the active site of aspartic proteinases (Asp-Thr-
Gly, residues 25 to 27), was very sensitive to mutagenesis:
69% of the substitution mutants tested failed to carry out
normal processing of the pol precursor (Fig. 4; Table 1). This
high level of sensitivity is contrasted with the lower level of
sensitivity to mutagenesis seen in the adjacent 13-amino-acid
domain: only 22% of the substitution mutants in this region
could not process the pol precursor (Fig. 5; Table 2). Thus,
the region of the HIV-1 PR that shows sequence identity
with the active site of aspartic proteinases is very sensitive
to mutagenesis, consistent with the idea that this region of
the PR is part of the active site and consistent with the
hypothesis that the HIV-1 PR shares a catalytic mechanism
with aspartic proteinases. A similar approach has been used
in which mutation of Asp-25 was shown to abolish process-
ing by the HIV-1 PR by using either a bacterial expression
system (23, 33) or a mutated virus (23), and an Asp-to-Ile
mutation was shown to block the activity of the Rous
sarcoma virus PR (25).
There are important differences between aspartic protein-
ases and the HIV-1 PR, most notably in size. Aspartic
proteinases consist of two similar lobes that are thought to
have arisen by gene duplication (39). Each lobe donates an
aspartic acid residue to the active site. The HIV-1 PR is
much smaller than the typical aspartic proteinase (11 versus
35 kDa), making it unlikely that one molecule of the viral PR
could provide both aspartic acid residues to the active site.
This has led to the suggestion that the PR must first dimerize
to form an active enzyme (35). The need to dimerize may
provide the virus with a mechanism for controlling the
activity of its PR. In at least one case it has been shown that
processing of viral proteins does not occur until the time of
virion formation (45). Such control of processing could be
achieved if the concentration of the gag-pol precursor is not
sufficiently high within the cell to permit dimer formation
until incorporation within the virion. When the gag-pol
precursor is concentrated during virion formation, dimeriza-
tion of the PR domain could occur, and processing of viral
proteins would proceed.
The PR cleavage site. The cleavage sites for retroviral PRs
have been deduced largely from the amino-terminal se-
quence of viral gag and pol proteins and by comparison of
the equivalent positions in genomes for which only the
nucleotide sequence is available (41). The cleavage sites
represent a family of sequences that are generally hydropho-
bic. Several schemes have been suggested to describe amino
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TABLE 3. Phenotypes of processing site mutants within HIV-1 pol precursor protein
Upstream PR (Phe-Pro) PR-RT (Phe-Pro) RT-IN (Leu-Phe)
Mutant Substitution Processing l | Mutant Substitution Processing Mutant Substitution ProcessingMutantSubsti ution LevelLelLvl
T4 Gly-Ala Wild type R5 Val-Gly Low Si Trp-Leu Negative
T12 Gly-His Wild type R17 Leu-Gly Low S3 Ile-Ser Negative
T19 Leu-Thr Wild type R9 Phe-Ser Low S6 Ile-Ala Negative
T28 Leu-Pro Wild type R2 Trp-Gly Negative S8 Thr-Gly Negative
T30 Ala-Ile Wild type R3 Arg-Leu Negative S11 Ala-Asp Negative
T8 Val-Arg Efficienta R7 Leu-Thr Negative S12 Phe-Thr Negative
T10 Arg-Thr Efficient' R10 Gly-Ser Negative S13 Gly-Arg Negative
T23 Ser-Thr Efficient' Rll Glu-Pro Negative S14 Arg-Leu Negative
T25 Gly-Arg Efficient' R13 Ser-His Negative S15 Ser-Met Negative
T26 Lys-Arg Efficient" R15 Leu-Leu Negative S17 Leu-Ser Negative
T3 Leu-Phe Lowa R16 Ser-Met Negative S18 Met-Thr Negative
T5 Val-Pro Low" R18 Thr-Leu Negative S20 Glu-Lys Negative
Tll Asp-Ser Lowa R21 Glu-Tyr Negative S22 Ser-Ser Negative
T14 Asn-Ser Lowa R22 Leu-Arg Negative S26 Cys-Met Negative
T15 Trp-Tyr Low" R23 Ala-Lys Negative S28 Arg-Asn Negative
T18 Ile-Pro Low" R25 Gly-Cys Negative S29 Ala-His Negative
T20 Ile-Gln Low" R26 Cys-Lys Negative S30 Ala-Leu Negative
R27 Gly-Ile Negative
R29 Pro-Trp Negative
a No upstream cleavage.
and Copeland (34) have proposed the following features of
the cleavage site: P4 (the fourth amino acid upstream of the
scissile bond) is the beta turner; P3 is polar; and P2 is
hydrophobic. Pearl and Taylor (L. H. Pearl and W. R.
Taylor, Letter, Nature (London) 328:482, 1987) have sug-
gested another scheme for those sites in which Pro is in the
P1' site: P2 is small; P1 is aromatic or large and hydrophobic;
and P2' (the second amino acid downstream of the scissile
bond) is small and hydrophobic. A more specific sequence
pattern has recently been suggested for primate lentivirus
cleavage sites (14). Deletion analysis of the HIV-1 pol
reading frame upstream of the PR cleavage site showed that
as few as four virus-specific amino acids are needed to define
the cleavage site to the left of the scissile bond (Fig. 2). In an
initial attempt to define the sequence requirement of the
cleavage site, we have also mutagenized the P1 site and the
P1' site of three PR cleavage sites in the HIV-1 pol precursor
(Fig. 6; Table 3). Two of these sites (upstream PR and
PR-RT) have Phe-Pro as the normal sequence, whereas the
third site (RT-IN) is Leu-Phe.
Although the data set for mutations at the three cleavage
sites is complex and incomplete, several points are apparent.
The first point is that certain types of amino acids are
tolerated in the P1 and the P1' sites. In P1, Gly and the
hydrophobic amino acids Ala, Val, Leu, and Phe are present
in the various substitutions that permit processing (although
Val appears only in the weakly processed mutant R5). The
amino acids Gly, Thr, Pro, Ser, Ala, His, and Ile are present
in P1' in cleavable mutants. With the exception of Ile and
His, the amino acids in the P1' site represent members of a
group of amino acid equivalents as defined by examining
evolutionarily related proteins (4). Like the other amino
acids in this group, Ile and His would be largely uncharged at
neutral pH. A more precise definition of the permitted amino
acids at these and surrounding positions will be obtained by
examination of a larger number of mutants. The second point
that can be made from these data is that the three cleavage
sites are not equivalent with respect to the P1 and P1' sites.
There are two examples, including one wild-type sequence,
in which a dipeptide sequence functioned at one cleavage
site but blocked cleavage at another processing site. Leu-
Phe, the wild-type sequence at the RT-IN site, blocked
cleavage when substituted at the upstream PR site; and
Leu-Thr was cleaved when substituted at the upstream PR
site but blocked cleavage when substituted at the PR-RT site
(Table 3). Thus, the amino acids flanking the scissile bond
are seen by the PR in a broader context that must include
surrounding amino acids.
Finally, two classes of mutants failed to process at the
upstream PR cleavage site (Table 3). One class processed the
other sites in the pol precursor efficiently, whereas the
second class did not. Examination of the amino acid substi-
tutions that make up these two classes reveals that the first
class contains positively charged amino acids in four of the
five mutants (the fifth is a Ser-Thr substitution), whereas the
second class contains pairs of amino acids, of which one has
a carbonyl group in the side chain, or pairs of hydrophobic
amino acids. One possible interpretation of these results is
that the positively charged residues (Arg and Lys) preclude
any binding to the PR substrate-binding site, leaving it
available to process at other sites. The second group of
mutants may mimic the normal cleavage site sufficiently to
permit binding by the PR but then remain in the substrate-
binding site and block the PR from cleavage at other sites.
Kotler et al. (24) have observed previously that the intro-
duction of Ile into the P1 site of a peptide substrate blocked
cleavage by the avian myeloblastosis virus PR and that this
peptide also tunctioned as an inhibitor.
The fact that inhibition of cleavage can occur at nonmu-
tated sites when the upstream PR site is mutated but not
when the RT-IN site is mutated suggests that there may be
ordered cleavage, with the upstream PR site cleaved before
the RT-IN site. The extreme phenotype seen in mutants with
mutations at the PR-RT site (Fig. 6, lanes 4 to 6) suggests
that this site may be cleaved first; this conclusion is consis-
tent with the structure of a reported processing intermediate
(11).
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